Ebola vaccine regimen generates strong immune response in children and adults in a clinical trial in Sierra Leone

Johnson & Johnson's two-dose Ebola vaccine regimen is safe, well tolerated and produces a strong immune response in people over the age of one, according to two new papers published in The Lancet Infectious Diseases.